Clinical trial
The Clinical Efficacy and Mechanism of SGLT2 Inhibitors Treating Polycystic Ovary Syndrome by Modulating the Nod-like Receptor Protein 3 Inflammasome
NCT05966792 is registered in ClinicalTrials.gov with Shanghai 10th People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Clinical Efficacy and Mechanism of SGLT2 Inhibitors Treating Polycystic Ovary Syndrome by Modulating the Nod-like Receptor Protein 3 Inflammasome
- Lead sponsor
- Shanghai 10th People's Hospital
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- November 10, 2023
- Completion date
- June 30, 2025
- Enrollment
- 82 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.